Samsung Bioepis Receives EU Bevacizumab Approval

Company Gets Fifth Biosimilar Approval By European Commision

 
• By Akriti Seth
  
Generate a summary of this article
Listen to this article
Beta

With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.

Oncology
Samsung Bioepis gets a second oncology biosimilar approval for Europe • Source: Shutterstock

Samsung Bioepis Co., Ltd. has received formal European Commission approval and marketing authorization for its Aybintio (bevacizumab) biosimilar. The nod follows an endorsement by the European Medicines Agency’s Committee for Medicinal Products for Human Use in June. Also see "Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown" - Generics Bulletin, 26 June, 2020.

The oncology biosimilar is the company’s fifth biosimilar approved for use in Europe following Benepali (etanercept), Flixabi (infliximab), Ontruzant (trastuzumab)...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.